FOXO4-DRI

FOXO4-DRI is a synthetic peptide that disrupts the FOXO4-p53 interaction inside senescent ('zombie') cells, triggering their selective apoptosis. It was developed by Peter de Keizer's lab at Erasmus University and is one of the most-discussed peptide-based senolytics — compounds that selectively kill senescent cells believed to drive many features of aging. The original 2017 paper in Cell received enormous attention for showing improvements in fur density, kidney function, and physical activity in aged mice. It is sold strictly for laboratory research.

As you age, your tissues accumulate 'zombie cells' — cells that should have died but instead linger around secreting inflammatory signals that damage nearby healthy tissue. FOXO4-DRI is a research peptide designed to kill these zombie cells selectively. In aged mice, treatment restored fur thickness, improved kidney markers, and increased physical activity — results that made headlines and gave senolytics a major popular moment. It is one of the most ambitious peptides in the longevity research space.

Senescent cells survive by depending on a FOXO4-p53 interaction that suppresses apoptosis. FOXO4-DRI is a D-retro-inverso peptide (more stable than natural L-amino acid versions) that competes with native FOXO4, freeing p53 to trigger apoptosis specifically in senescent cells. Healthy non-senescent cells are largely unaffected because they do not depend on this interaction for survival.

• •Senescent cell clearance in aged tissue
• •Fur and skin regeneration in mice
• •Kidney function in aged animals
• •Chemotherapy-induced senescence research
• •Senolytic pharmacology and combination therapy

FOXO4-DRI is a longevity-forum and biohacker favorite. Discussion centers on the de Keizer mouse study, comparisons to small-molecule senolytics like dasatinib + quercetin and fisetin, and the practical difficulties of synthesizing a stable D-retro-inverso peptide. Forum protocols are highly cautious and typically infrequent (every few weeks or months) given the powerful apoptotic mechanism.

“A peptide that tells zombie cells to die.”

FOXO4-DRI is sometimes discussed alongside fisetin, quercetin, or dasatinib in 'senolytic stack' protocols — combining peptide and small-molecule mechanisms. Combinations are theoretical and not based on published clinical data.

FOXO4-DRI is a synthetic D-retro-inverso peptide senolytic that selectively kills senescent cells by disrupting the FOXO4-p53 interaction. The original 2017 mouse study showed remarkable age-related improvements. It remains preclinical and is sold for laboratory research only.